Manufacturers Increase Availability of Treatment Options amid COVID-19 Pandemic
Acute exacerbation of CRS (Chronic Rhinosinusitis) is regarded as a serious airway disease. According to the World Health Organization (WHO) recommendations, it may be a risk factor for exposure to COVID-19 as well as for existing COVID-19 positive patients. Hence, companies in the acute exacerbation of CRS treatment market are increasing the availability of treatments and medicines to reduce morbidity and mortality of patients.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111799
Manufacturers in the acute exacerbation of CRS treatment market are boosting their production capacities in intranasal corticosteroids that are considered as the gold standard for CRS in patients with coronavirus. Stakeholders are gaining awareness about reducing surgical treatments to the minimum. Treatment with biologics is being recommended with careful monitoring in non-infected patients and should be temporarily interrupted during COVID-19 infection.
Biologics Hold Promising Potentials for CRSwNP Patients Before Initial Surgery
CRS with nasal polyps (CRSwNP) is a common and heterogeneous inflammatory disease of the upper respiratory tract. Despite the potential value of biomarker-based endotyping to provide guidance regarding optimal care and treatment choices for patients with CRSwNP, the current practice is largely not biomarker-based. This explains why the acute exacerbation of CRS treatment market is slated to register a CAGR of 4.6% from 2021 to 2031. Hence, companies are now increasing focus on biologics, especially for patients before considering initial surgery.
Patients with comorbid severe asthma and for whom surgery is less available are opting for biologics. Biologics are being recommended for use immediately following surgery in patients who have a history of nasal polyp recurrence within 12 months of a prior surgery.
Antibiotics Help in Treatment of Patients with Severe Asthma, CRS
Severe asthma and acute exacerbation of CRS lead to frequent comorbidities, thus complicating the overall management of the disease. Biomarkers such as absolute eosinophil count in peripheral blood and fractional exhaled nitric oxide (FeNO) may be used as indicators of type 2 asthma endotypes and help predict response to biologic therapies.
There is data indicating that the presence of CRS is associated with worse outcomes in patients with asthma, more specifically with increased risk of frequent exacerbations. Hence, companies in the acute exacerbation of CRS treatment market are increasing their production capabilities in antibiotics, oral analgesics, and intranasal steroids, among other treatment options to improve patient outcomes.
Individualized Treatment with Antibiotics Improves Patient Quality of Life
Defining acute exacerbations of CRS with quantifiable clinical and immunologic metrics has remained a challenge due to the complex etiology of acute exacerbations and the inconsistency in endpoint reporting. Current recommendations for treatment of acute exacerbation of CRS continue to suggest blanket medical intervention, including short-course antibiotic treatment. Companies in the acute exacerbation of CRS treatment market are increasing R&D to improve methods for clinically defining the disease and its risk factors to facilitate individualized treatment.
Manufacturers in the acute exacerbation of CRS treatment market are boosting their output capacities in first-line antibiotic therapies such as amoxicillin, with or without clavulanate to improve patient quality of life.
Healthcare providers are closely monitoring the COVID-19 situation and have recommended aligning any diagnostic and treatment operations with guidance from the WHO and Centers for Disease Control and Prevention (CDC). The acute exacerbation of CRS treatment market is expected to reach US$ 7.06 Bn by 2031. Though available biological agents have therapeutic effects for patients with asthma and CRS, the improvement of nasal symptoms is less evident, despite reaching satisfactory asthma control. Hence, companies should improve their knowledge in potential therapeutic agents and increase the ability of biological agents to equally reach different tissues in order to improve patient outcomes.
Acute Exacerbation of CRS Treatment Market: Overview
Rhinosinusitis is a serious health issue that affects people all over the world. It’s a sinus infection that starts in the nasal passages and spreads to the paranasal sinuses. Nasal blockage, purulent nasal discharge, and face pain-pressure-fullness are the three main symptoms. The patient defines nasal obstruction as obstruction, congestion, blockage, or stuffiness; purulent nasal discharge is hazy or colored in appearance; and facial pain-pressure-fullness affects the anterior face and periorbital area, or presents as headache that can be localized or widespread.
The acute exacerbation of CRS treatment market is anticipated to be driven by the increase in rhinosinusitis patients during the forecast period. In 2018, the CDC estimated that 28.9 million individuals in the U.S. were diagnosed with rhinosinusitis.
View full report@ https://qyresearchmedical.com/report/acute-exacerbation-of-crs-treatment-market-treatment-antibiotics-leukotriene-inhibitors-antihistamines-mucolytics-decongestants-nasal-saline-irrigation-oral-corticosteroids-endoscopic-sinus-surgery-and-oth-2021-2030/111799
Acute Exacerbation of CRS Treatment: Market Drivers
Acute CRS exacerbation is gaining traction due of its considerable impact on patients’ quality of life and healthcare costs. Acute CRS exacerbation is a kind of CRS that is started by viruses and subsequently followed by bacterial infections, which may be the result of a bacterial species imbalance inside the sinus cavities.
Understanding the etiology and immunological mechanisms of acute CRS exacerbation has increased significantly. However, there is currently no consensus definition, diagnostic criteria, biomarkers to distinguish acute CRS exacerbation from CRS, illness severity assessment, or evidence-based therapy choices for acute CRS exacerbation.
Rise in mucosal inflammation incidences leading to rhinosinusitis is expected to drive the demand for acute CRS exacerbation treatment over the next few years
Demand for acute CRS exacerbation treatment is expected to further increase due to rise in patient awareness about sinusitis treatment. New products and device development in the field of acute CRS exacerbation are also projected to significantly propel the market.
Surge in Product Launches and Approvals
In December 2020, AstraZeneca announced gaining marketing authorization from the Drugs Controller General of India (DCGI) for use of the original research medicine, Fasenra (Benralizumab solution, for injection in a single dose prefilled syringe30 mg/ml subcutaneous administration only) in patients with severe asthma (eosinophilic asthma) or chronic rhinosinusitis. Benralizumab (Fasenra) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients or patients with chronic rhinosinusitis. Rising number of product approvals is expected to drive the market during the forecast period.
Market Segmentation: Acute Exacerbation of CRS Treatment Market
In terms of treatment, the global acute exacerbation of CRS treatment market has been classified into antibiotics, leukotriene inhibitors, antihistamines, mucolytics, decongestants, nasal saline irrigation, oral corticosteroids, endoscopic sinus surgery, and others
In terms of route of administration, the global acute exacerbation of CRS treatment market has been segregated into topical, nasal, oral, and injectable
Based on distribution channel, the global acute exacerbation of CRS treatment market has been categorized into online pharmacies, retail pharmacies, and hospital pharmacies
Based on infection type, the global acute exacerbation of CRS treatment market has been bifurcated into staphylococcus species and others
Each of the segments has been analyzed in detail for acute exacerbation of CRS treatment trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The acute exacerbation of CRS treatment market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.
Regional Overview: Acute Exacerbation of CRS Treatment Market
In terms of region, the global acute exacerbation of CRS treatment market has been divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been further divided into major countries and sub-regions.
North America accounted for a prominent share of the global market for acute exacerbation of CRS treatment in 2020. North America is expected to retain its market share during the forecast period primarily due to rise in cases of rhinosinusitis in the U.S. For instance, rhinosinusitis accounted for around 12 to 17 million annual visits to physicians and 12% of antibiotics prescribed to geriatric patients in the U.S., making it one of the 10 most common conditions to be treated in ambulatory practice. Hence, increase in cases of acute rhinosinusitis is projected to fuel the global acute exacerbation of CRS treatment market.
Asia Pacific is likely to increase its market share by the end of the forecast period. Product launches, acquisitions, distribution agreements, alliances, and geographical expansion by local players, especially in China and India, are anticipated to drive the acute exacerbation of CRS treatment market in the region. Surge in healthcare expenditure and rise in awareness about sinusitis are projected to drive the market in the region.
Demand for acute exacerbation of CRS treatment is also driven by expansion of major industries and the launch of acute exacerbation of CRS treatment by major companies in the region
Current and future market sizes in terms of value (US$ Mn) of these regional markets and major countries have been provided in the report for the period from 2017 to 2031, along with their CAGRs for the period from 2021 to 2031
The study also offers a list of recommendations, highlights, and useful insights of the market, which are estimated to help new companies willing to enter the market and existing companies to increase market share and in the decision-making process.
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111799/2900
The report concludes with the company profiles section that includes key information about the major players in the global acute exacerbation of CRS treatment market
Leading players analyzed in the report are
- Sun Pharmaceutical Industries, Inc.
- Pfizer Inc.
- Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- Fresenius Kabi USA, LLC
- Dr. Reddy’s Laboratories, Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Abbott Laboratories
- Bayer AG
- Eli Lilly And Company
- Bristol-Myers Squibb
- Merck & Co, Inc.
- AstraZeneca Plc
- Amneal Pharmaceuticals LLC
- GlaxoSmithKline plc.
- Aurobindo Pharma
- Hikma Pharmaceuticals plc
- Mylan N.V.
Each of these players has been profiled in the report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments
Key Questions Answered in Acute Exacerbation of CRS Treatment Report
- What is the sales/revenue generated by acute exacerbation of CRS treatment products across all regions during the forecast period?
- What are the opportunities in the global acute exacerbation of CRS treatment market?
- What are major drivers, restraints, opportunities, and threats in the global market?
- Which region is set to expand at the fastest CAGR during the forecast period?
- Which treatment segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
Acute Exacerbation of CRS Treatment Market – Segmentation
- Leukotriene Inhibitors
- Nasal Saline Irrigation
- Oral Corticosteroids
- Endoscopic sinus surgery
Route of Administration
- Online Pharmacies
- Retail Pharmacies
- Hospital Pharmacies
- Staphylococcus Species
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Exacerbation of CRS Treatment Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.3. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, 2017–2030
5. Market Outlook
5.1. Clinical Trials & Regulatory Approvals Analysis
5.2. List of Brand / Product Approved
5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
5.4. Technological Advancements
5.5. Disease Prevalence & Incidence
6. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2030
6.2.1. Acute Exacerbation of CRS
188.8.131.52. Leukotriene Inhibitors
184.108.40.206. Nasal Saline Irrigation
220.127.116.11. Oral Corticosteroids
18.104.22.168. Endoscopic sinus surgery
6.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration
7. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Route of Administration2017–2030
7.2.1. Acute Exacerbation of CRS
7.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Route of Administration
8. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Acute Exacerbation of CRS Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2030
8.2.1. Acute Exacerbation of CRS
22.214.171.124. Online Pharmacies
126.96.36.199. Retail Pharmacies
188.8.131.52. Hospital Pharmacies
8.3. Global Acute Exacerbation of CRS Treatment Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Exacerbation of CRS Treatment Market Analysis and Forecast, by Infection Type
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111799/2900
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us: